Traders Watch List: MPLX LP (NYSE:MPLX), Visa Inc. (NYSE:V), Mastercard Inc. (NYSE:MA), Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Posted by on Apr 23, 2014

MPLX LP (NYSE:MPLX) a master limited partnership sponsored by Marathon Petroleum Corporation, will host a conference call on Thursday, May 1, at 2 p.m. EDT to discuss 2014 first-quarter financial results, which will be released earlier that day, and to provide an update on partnership operations. MPLX LP (NYSE:MPLX) shares after opening at $55.17 moved to $56.50 on last trade day and at the end of the day closed at $56.50. Company price to sales ratio in past twelve months was calculated as 8.76 and price to cash ratio as 78.77. MPLX LP (NYSE:MPLX) showed a positive weekly performance of 9.45%.

On Wednesday, Visa Inc. (NYSE:V) will be reporting their Q1 results and analysts are already recommending BUY V. Robert W. Baird analyst, David Koning, recently recommended BUY Visa and has already seen a positive return. Visa Inc. (NYSE:V) shares advanced 0.40% in last trading session and ended the day on $209.97. V return on equity ratio is recorded as 23.60% and its return on assets is 17.90%. Visa Inc. (NYSE:V) yearly performance is 29.36%.

MasterCard International Inc. (NYSE:MA) will buy Sydney, Australia-based loyalty and rewards services provider Pinpoint Pty Ltd, in a deal designed to enhance the rewards programs that MasterCard can offer to its customers. Mastercard Inc. (NYSE:MA) shares moved up 0.30% in last trading session and was closed at $74.53, while trading in range of $73.85 – $74.77. Mastercard Inc. (NYSE:MA) year to date (YTD) performance is -10.54%.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is beginning early-stage clinical trials of its cancer drug, Selinexor, on children with relapsed or resistant forms of leukemia. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) weekly performance is -18.26%. On last trading day company shares ended up $28.16. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) distance from 50-day simple moving average (SMA50) is -22.89%. Analysts mean target price for the company is $48.25.

Leave a Reply

Your email address will not be published. Required fields are marked *